4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -140.11M | -209.18M | -196.14M | -176.44M | -160.87M |
| Total Depreciation and Amortization | 7.63M | 7.43M | 7.13M | 6.87M | 6.71M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.23M | 18.55M | 19.46M | 19.43M | 19.04M |
| Change in Net Operating Assets | 6.17M | -301.00K | 3.16M | -3.11M | 537.00K |
| Cash from Operations | -109.08M | -183.50M | -166.39M | -153.26M | -134.59M |
| Capital Expenditure | -536.00K | -1.56M | -3.42M | -3.71M | -3.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.44M | 44.49M | 55.88M | -3.52M | -298.65M |
| Cash from Investing | -92.97M | 42.93M | 52.46M | -7.23M | -302.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 112.96M | 1.58M | 2.03M | 18.42M | 337.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 112.96M | 1.58M | 2.03M | 18.42M | 337.25M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.10M | -138.98M | -111.90M | -142.07M | -99.77M |